IP Library Patent Application 16242757
Patent Application
App. No. 16/242,757

Treatment of Mild and Moderate Alzheimer's Disease

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/242,757
Abstract

The present invention relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine (“COMPOUND I”) or a pharmaceutically acceptable salt thereof. In various embodiments, the methods of treatment include treatment of mild-to-moderate dementia of Alzheimer's type, diabetes, insomnia, and other indications. The present invention also relates to pharmaceutical compositions comprising COMPOUND I or a pharmaceutically acceptable salt thereof.

Claims (11)

1 . A method for treating diabetes comprising administering to a subject in need thereof an amount less than 20 mg per day of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine or a pharmaceutically acceptable salt thereof.

2 . The method of claim 1 , wherein the [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine is administered in a dose ranging from about 1 to about 20 mg per day.

3 . A method for inhibiting the reduction of glucose metabolism associated with the regression of subjects with mild-to-moderate Alzheimer's disease, comprising administering to a subject in need thereof an amount less than 20 mg per day of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine or a pharmaceutically acceptable salt thereof.

4 . The method of claim 3 , wherein the dose is about 5 mg per day or about 4 mg per day or about 3 mg per day or about 2 mg per day.

5 . The method of claim 3 , wherein the method of treatment further comprises administering to the subject an acetylcholinesterase inhibitor (AChEI).

6 . The method of claim 5 , wherein the AChEI is selected from the group consisting of donepezil hydrochloride, galantamine hydrochloride, rivastigmine tartrate, and tacrine hydrochloride.

7 . The method of claim 3 , wherein the method of treatment further comprises administering to the subject memantine hydrochloride.

8 . The method of claim 1 , wherein treatment of diabetes comprises lowering blood glucose levels in the subject.

9 . The method of claim 8 , wherein the subject is suffering from mild-to-moderate Alzheimer's Disease.

10 . The method of claim 8 , wherein the subject's blood glucose levels are reduced by at least 5 mg/dl.

11 . The method of claim 8 , wherein the subject's naïve glucose level is greater than 100 mg/dl.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2019
From: ORLANDI, CESARE; GRIMES, IMOGENE M.; VALCARCE LOPEZ, MARIA CARMEN; KOSTURA, MATTHEW J.
To: TRANSTECH PHARMA, INC.
Reel/Frame 047955/0272 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2019
From: TRANSTECH PHARMA, INC.
To: TRANSTECH PHARMA, LLC
Reel/Frame 047955/0296 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2019
From: CLARK, DAVID J.
To: TRANSTECH PHARMA, LLC
Reel/Frame 047955/0322 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2019
From: VTVX HOLDINGS I LLC
To: VTV THERAPEUTICS LLC
Reel/Frame 047955/0389 →
CHANGE OF NAME Recorded Jan 10, 2019
From: TRANSTECH PHARMA, LLC
To: VTV THERAPEUTICS LLC
Reel/Frame 048044/0409 →
CHANGE OF NAME Recorded Jan 10, 2019
From: VTV THERAPEUTICS LLC
To: VTVX HOLDINGS I LLC
Reel/Frame 048044/0415 →